Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Based on western blot testing, ...
– PBGENE-DMD treatment in a humanized DMD mouse model demonstrates improvements in muscle pathology and biomarkers of muscle damage – – PBGENE-DMD shows durable dystrophin protein restoration in ...
A new treatment platform developed by researchers at the University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
SGT-003 gene therapy showed significant microdystrophin expression and muscle integrity improvements in DMD patients, with no serious adverse events reported. The novel AAV vector demonstrated ...
Home videos shared with Regenxbio show boys who received RGX-202 jumping up off the ground, racing up the stairs and even bouncing on a trampoline. (iStock / Getty Images Plus) Regenxbio’s gene ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Duchenne muscular dystrophy is a genetic disorder that leaves people unable to make an important protein called dystrophin, resulting in muscle weakness and degeneration Current viral-based gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results